These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2663231)

  • 21. [Methods of determination of fibrin fibrinogen degradation products (review of the literature)].
    Guseínov ChS; Prozorovskaia NN; Mikhaĭlova ND; Gorelova AM; Lagutina NIa
    Lab Delo; 1978; (5):259-66. PubMed ID: 79007
    [No Abstract]   [Full Text] [Related]  

  • 22. [Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct].
    Belousov IuB; Panchenko EP; Pivovarov VA; Nemiro VK
    Kardiologiia; 1979 Aug; 19(8):87-91. PubMed ID: 491364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal haemostasis and blood viscosity in malignant hypertension.
    Isles C; Lowe GD; Rankin BM; Forbes CD; Lucie N; Lever AF; Kennedy AC
    Thromb Haemost; 1984 Dec; 52(3):253-5. PubMed ID: 6241751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Soluble fibrin monomer complexes in thromboembolism].
    Gryglik J
    Przegl Lek; 1982 Sep; 39(8):551-3. PubMed ID: 6753042
    [No Abstract]   [Full Text] [Related]  

  • 25. [Importance of a determining fibrinogen derivatives in physiological pregnancy and in pregnancy complicated by nephropathy].
    Makatsariia AD; Bokarev IN; Mel'nikov AP; Detitkina GN
    Akush Ginekol (Mosk); 1978 Mar; (3):64-5. PubMed ID: 646068
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparative study of the properties of a fibrinogen--heparin complex produced in vitro and one isolated from a plasma fraction of fibrinogen degradation products].
    Kudriashov BA; Liapina LA; Zhitnikova ES; Kriukova MG
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1979; (9):58-62. PubMed ID: 497299
    [No Abstract]   [Full Text] [Related]  

  • 27. [Changes in the content of fibrinogen and its high-molecular derivatives as affected by the physical training of ischemic heart disease patients].
    Dudaev VA; Diukov IV; Borodkin VV
    Ter Arkh; 1986; 58(12):62-7. PubMed ID: 3824217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunction.
    Sørensen JV; Jensen HP; Rahr HB; Borris LC; Lassen MR; Fedders O; Haase JP; Knudsen F
    Haemostasis; 1993; 23(2):91-7. PubMed ID: 8365691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An analysis of a disorder in the fibrin-forming phase in virtually healthy middle-aged and elderly subjects by using the ancistron test].
    Platonova TN; Sushko OO; Lukinova NI; Solovĭov DA
    Fiziol Zh (1994); 1994; 40(3-4):63-70. PubMed ID: 7621957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures.
    Lipinska I; Lipinski B; Gurewich V; Hoffmann KD
    Am J Clin Pathol; 1976 Dec; 66(6):958-66. PubMed ID: 998569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.
    Regañón E; Vila V; Aznar J; Garrido G; Estellés A; Berenguer J
    Thromb Res; 1987 Jun; 46(5):705-14. PubMed ID: 3629544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rocket immunoelectrophoresis for the rapid quantitation of plasma fibrinogen.
    Saoji AM; Jad CY; Kelkar SS
    Indian J Pathol Microbiol; 1984 Jan; 27(1):1-5. PubMed ID: 6511021
    [No Abstract]   [Full Text] [Related]  

  • 33. The plasma cryofibrinogen of calves infected with Oesophagostomum radiatum.
    Goodger BV; Bremner KC
    Z Parasitenkd; 1979 Dec; 60(3):239-47. PubMed ID: 543212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease.
    Shainoff JR; Valenzuela R; Urbanic DA; DiBello PM; Lucas FV; Graor R
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):499-503. PubMed ID: 1983461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
    Horan JT; Francis CW
    Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates.
    Gurewich V; Lipinska I; Lipinski B
    Thromb Res; 1974 Nov; 5(5):647-56. PubMed ID: 4445987
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasmin lysis of fibrinogen and fibrin and the antigenic properties of their degradation products.
    Ekert H; Muntz RH
    Br J Haematol; 1972 Jan; 22(1):103-10. PubMed ID: 4258329
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.
    Brody JI
    J Clin Pathol; 1972 Sep; 25(9):754-6. PubMed ID: 5086217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.